Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Methylphenidate
Drug ID BADD_D01431
Description Methylphenidate is a central nervous system stimulant used most commonly in the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) and for narcolepsy. Also known as the marketed products Ritalin, Concerta, or Biphentin, methylphenidate is used with other treatment modalities (psychological, educational, cognitive behaviour therapy, etc) to improve the following group of developmentally inappropriate symptoms associated with ADHD: moderate-to-severe distractibility, short attention span, hyperactivity, emotional lability, and impulsivity. Long-acting formulations of psychostimulants such as methylphenidate, [DB01576], and [DB01255] are considered the most effective and widely used treatment for ADHD, and are considered first-line options for children, adolescents, and adults as recommended by CADDRA (Canadian ADHD Resource Alliance). [L6037] CADDRA recommends the use of methylphenidate due to long term studies, of over twenty years in duration, which show methylphenidate is safe and effective.
Indications and Usage Methylphenidate is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients 6 years of age and older and for the treatment of narcolepsy.
Marketing Status approved; investigational
ATC Code N06BA04
DrugBank ID DB00422
KEGG ID D04999
MeSH ID D008774
PubChem ID 4158
TTD Drug ID D02PPN
NDC Product Code 0781-2363; 0378-8263; 0574-2420; 0406-7654; 70165-200; 0378-8261; 68968-5552; 68968-5555; 70165-100; 0781-2362; 0781-2364; 0378-8262; 0574-2410; 0574-2430; 0574-2415; 68968-5553; 70165-300; 68968-5554; 0781-2361; 0378-8260
UNII 207ZZ9QZ49
Synonyms Methylphenidate | Metadate | Equasym | Methylin | Concerta | Phenidylate | Ritalin | Ritaline | Ritalin-SR | Ritalin SR | Tsentedrin | Centedrin | Daytrana | Methylphenidate Hydrochloride | Hydrochloride, Methylphenidate
Chemical Information
Molecular Formula C14H19NO2
CAS Registry Number 113-45-1
SMILES COC(=O)C(C1CCCCN1)C2=CC=CC=C2
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
White blood cell count abnormal13.01.06.028--Not Available
Withdrawal syndrome19.07.06.023; 08.06.02.0120.000658%Not Available
Hypervigilance19.01.02.0060.000041%Not Available
Agnosia19.21.01.006; 17.02.03.0120.000041%Not Available
Energy increased08.01.03.0170.000230%Not Available
Hypoacusis04.02.01.006--
Performance status decreased08.01.03.0420.000193%Not Available
Application site vesicles08.02.01.009; 23.03.01.009; 12.07.01.0090.000349%Not Available
Application site dryness23.03.03.024; 12.07.01.011; 08.02.01.0110.000300%Not Available
Autoimmune thyroiditis10.04.08.006; 05.02.04.0020.000041%Not Available
Spontaneous penile erection21.03.01.0100.000132%Not Available
Sudden cardiac death08.04.01.008; 02.03.04.016--Not Available
Tachyarrhythmia02.03.02.0080.000041%Not Available
Homicidal ideation19.05.01.0080.000201%Not Available
Left ventricular dysfunction02.04.02.0110.000062%
Left ventricular hypertrophy02.04.02.0140.000041%Not Available
Muscle tightness15.05.03.0070.000193%Not Available
Impatience19.05.01.0140.000062%Not Available
Cardiac death08.04.01.007; 02.03.04.015--Not Available
Bradyphrenia19.10.03.002; 17.03.03.0040.000041%Not Available
Abulia17.02.05.040; 19.01.02.0090.000041%Not Available
Sudden onset of sleep17.15.04.003--Not Available
Application site urticaria23.04.02.002; 12.07.01.028; 10.01.06.002; 08.02.01.0280.001069%Not Available
Pneumomediastinum22.09.03.0040.000041%Not Available
Reversible ischaemic neurological deficit17.08.01.074; 24.04.06.012--Not Available
Ventricular hypokinesia02.04.02.0130.000041%Not Available
Contusion23.03.11.002; 12.01.06.001; 15.03.05.007; 24.07.06.001--
Self-injurious ideation19.12.01.0070.000090%Not Available
Madarosis06.06.04.010; 23.02.02.0040.000041%Not Available
Acute coronary syndrome24.04.04.011; 02.02.02.015--Not Available
The 17th Page    First    Pre   17 18 19 20 21    Next   Last    Total 23 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene